Clinical benefits of PD-1 inhibitors in specific subgroups of patients with advanced esophageal squamous cell carcinoma: a systematic review and meta-analysis of phase 3 randomized clinical trials.

Front Immunol · 2023 · PMC10185849 · PMID 37205107

Europe PMC DOI

hedged sentences

0.0700

closest p · 1.4× alpha

0.3000

boldest claim

The sentences

a near-significant trendP = 0.070so close (0.05 < p ≤ 0.1)

The difference in PFS benefits across treatment line subgroups was observed as a near-significant trend (P = 0.070) ( Figure 2B ). 3.3.

also in 39 other papers

did not reach statistical significanceP = 0.300not close (p > 0.1)

The survival benefit was similar in first-line treatments and second-line treatments as the difference did not reach statistical significance (OS: P = 0.300; PFS: P = 0.070; ORR: P=0.780; DOR: P=0.154) ( Figure 2 ).

also in 17,681 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.